A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (clinicaltrials.gov) - Apr 18, 2026 - P1 | N=9 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=42 ➔ 9 | Trial completion date: Jan 2027 ➔ Feb 2026 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2026 ➔ Feb 2026; Patient recruitment problems
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Hodgkin Lymphoma • Multiple Myeloma • Oncology
|